# APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Study · id `cardio:ct-nct03997383` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03997383](<https://clinicaltrials.gov/study/NCT03997383>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03997383

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

## Technical summary

Registry record NCT03997383. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-04 (actual); primary completion 2022-06-20 (actual). Results posted on 2023-10-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 360 participants (enrolled count; ClinicalTrials.gov record NCT03997383, source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)
- Started: 2019-09-04 (actual) (ClinicalTrials.gov record NCT03997383, source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)
- Primary completion: 2022-06-20 (actual) (ClinicalTrials.gov record NCT03997383, source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)
- Completion: 2025-12-24 (actual) (ClinicalTrials.gov record NCT03997383, source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)
- Results first posted: 2023-10-18 (ClinicalTrials.gov record NCT03997383, source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Chile; Czechia; Denmark; France; Hong Kong SAR China; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; South Korea; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT03997383, source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03997383-2026-04-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
- Condition: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Drug): Placebo
- Intervention (Drug): Patisiran
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis (`cardio:pubmed-37888916`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patisiran Treatment in the Brazilian Subpopulation of the Phase 3 APOLLO-B Study in Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis (`cardio:pubmed-40243852`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5f89025ef6c76d17f05e886f5f9a4484db12015ddb667d5f6ad1dc3e2f06b182
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
